A. Vindevoghel

2.0k citations

23 papers · 868 indexed · h-index 10

Cancer Research top 5%
- Breast Cancer Treatment Studies 14
Oncology top 5%
- Cancer Treatment and Pharmacology 10
- HER2/EGFR in Cancer Research 5
- Colorectal Cancer Treatments and Studies 3
Pathology and Forensic Medicine top 10%
- Breast Lesions and Carcinomas 3
Dermatology top 10%
Genetics
- Estrogen and related hormone effects 5
Pulmonary and Respiratory Medicine
- Advanced Breast Cancer Therapies 2
- Gastric Cancer Management and Outcomes 2

Co-authors: M. Beauduin Martine Piccart Henri Roché Patrice Viens Bernard Asselain Alain Monnier Jean Genève M. Spielmann
Cited by: Cancer Research Oncology Pathology and Forensic Medicine
Journals: Journal of Clinical Oncology (5 papers)European Journal of Cancer (5 papers)Annals of Oncology (2 papers)
Partner nations: Belgium Italy Luxembourg

In The Last Decade

A. Vindevoghel

23 papers receiving 832 citations

Peers

Countries citing papers authored by A. Vindevoghel

Since Specialization

Citations

This map shows the geographic impact of A. Vindevoghel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Vindevoghel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Vindevoghel more than expected).

Fields of papers citing papers by A. Vindevoghel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Vindevoghel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Vindevoghel. The network helps show where A. Vindevoghel may publish in the future.

Co-authorship network

The 25 scholars most cited alongside A. Vindevoghel, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with A. Vindevoghel Line = papers co-authored together A. Vindevoghel links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Cardiac assessment of early breast cancer patients 18years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy European Journal of Cancer ·Evandro de Azambuja,Lieveke Ameye,M. S. Sivagamasundari,Michal Raus,Philippe Aftimos,R. Dandliker,Shih‐Li Chao,R.V. Sorokatuy,C. Focan,Nathalie Cornez,A. Vindevoghel,M. Beauduin,Marc Lemort,Marianne Paesmans,Thomas Suter,Martine Piccart	2015	29
2	The EORTC 10041/BIG 03-04 MINDACT trial is feasible: Results of the pilot phase European Journal of Cancer ·Emiel J. Rutgers,Martine Piccart,Jan Bogaerts,Suzette Delaloge,Laura van ‘t Veer,Isabel T. Rubio,Giuseppe Viale,Alastair M. Thompson,Rodolfo Passalacqua,Ulrike Nitz,A. Vindevoghel,Jean‐Yves Pierga,Peter M. Ravdin,Gustavo Werutsky,Fátima Cardoso	2011	67
3	Five-Year Analysis of the FNCLCC-PACS04 Trial: FEC100 vs ED75 for the Adjuvant Treatment of Node Positive Breast Cancer. Cancer Research ·Henri Roché,Djelila Allouache,Gilles Romieu,Hugues Bourgeois,Jean-Luc Canon,D. Serin,И.Г. Бастракова,L. Mauriac,Alain Monnier,A. Vindevoghel,Nadine Dohollou,É. Luporsi,Jean-Marc Ferrero,B. Audhuy,Camile Jequiez,Laurent Cany,Étienne Brain,M.M. Jimenez,Lise Roca,M. Spielmann	2009	8
4	Long-Term Benefit of High-Dose Epirubicin in Adjuvant Chemotherapy for Node-Positive Breast Cancer: 15-Year Efficacy Results of the Belgian Multicentre Study Journal of Clinical Oncology ·Evandro de Azambuja,Marianne Paesmans,M. Beauduin,A. Vindevoghel,Nathalie Cornez,Juliana Danielo Fachin,F. Ries,Rebecca M. Steiner,Joseph Kerger,G. W. C. Tait,Christian Focan,Rizkiatul Paidiah,Stella Dolci,J.-M. Nogaret,Angelo Di Leo,Martine Piccart	2008	21
5	Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial Journal of Clinical Oncology ·Henri Roché,P. Fumoleau,M. Spielmann,Jean-Luc Canon,T. Delozier,Daniel Serin,Michel Symann,Pierre Kerbrat,P Soulié,Sara Hofmann,Patrice Viens,Alain Monnier,A. Vindevoghel,Mario Campone,Marie-Josèphe Goudier,Jacques Bonneterre,Jean-Marc Ferrero,Anne‐Laure Martin,Jean Genève,Bernard Asselain	2006	401
6	Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide (EC or HEC) with cyclophosphamide, methotrexate, and fluorouracil (CMF) in 777 women with node-positive (N+) breast cancer (BC): 10-year follow-up results Journal of Clinical Oncology ·Evandro de Azambuja,Marianne Paesmans,日原美和子,M. Beauduin,A. Vindevoghel,Nathalie Cornez,C Focan,Rizkiatul Paidiah,J.-M. Nogaret,M. Piccart-Gebhart	2006	2
7	The feasibility of classical cyclophosphamide, methotrexate, 5-fluorouracil (CMF) for pre- and post-menopausal node-positive breast cancer patients in a Belgian multicentric trial: a study of consistency in relative dose intensity (RDI) and cumulative doses across institutions Annals of Oncology ·Valery YEZERSKY,Angelo Di Leo,Marianne Paesmans,M. Beauduin,A. Vindevoghel,Eric Klein,C Focan,Ahmad Awada,Fátima Cardoso,Stella Dolci,S. Bartholomeus,Martine Piccart	2002	5
8	Adjuvant high-dose medroxyprogesterone acetate for early breast cancer: 13 years update in a multicentre randomized trial British Journal of Cancer ·(unknown),C. Focan,M. Beauduin,E. Salamon,Jacques De Grève,Viviana Otálvaro G.,J.P. Lobelle,F. Majois,Rizkiatul Paidiah,Jan Tytgat,Sebastian Belle,周子花山,A. Vindevoghel	2001	27
9	HER-2 and topo-isomerase IIα as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide Annals of Oncology ·Angelo Di Leo,Denis Larsimont,David Gancberg,Tero A.H. Järvinen,M. Beauduin,A. Vindevoghel,Eric Klein,C Focan,F. Ries,徳壽志賀,Rebecca M. Steiner,Stella Dolci,Ghizlane Rouas,Marianne Paesmans,J.P. Lobelle,Jorma Isola,Martine Piccart	2001	87
10	Phase III Trial Comparing Two Dose Levels of Epirubicin Combined With Cyclophosphamide With Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer Journal of Clinical Oncology ·Martine Piccart,Angelo Di Leo,M. Beauduin,A. Vindevoghel,H Dinerman,C. Focan,Rizkiatul Paidiah,F. Ries,G. W. C. Tait,Juliana Danielo Fachin,Rebecca M. Steiner,文彦山路,Joseph Kerger,Jonna Lind,Sylvie Beauvois,S. Bartholomeus,Stella Dolci,J.P. Lobelle,Marianne Paesmans,J.-M. Nogaret	2001	119
11	HER-2 amplification evaluated by fluorescence in-situ hybridization (FISH) as a predictive marker in node-positive (N+) breast cancer (BC) patients (pts) randomly treated with CMF or an anthracycline-based therapy European Journal of Cancer ·Angelo Di Leo,David Gancberg,Denis Larsimont,Ghizlane Rouas,A. Vindevoghel,C. Focan,M. Beauduin,Stella Dolci,Marianne Paesmans,Martine Piccart	2001	13
12	Adjuvant intraportal chemotherapy for Dukes B2 and C colorectal cancer also receiving systemic treatment: results of a multicenter randomized trial Anti-Cancer Drugs ·C. Focan,J Bury,M. Beauduin,Anna Emde,A. Vindevoghel,青山栄一,Luca Fezzi	2000	8
13	BRCA1 and BRCA2 mutations in Belgian families with a history of breast and/or ovarian cancer European Journal of Cancer Prevention ·lJiajun Geng,Olivier Froment,Kusuma Nirmala Widyasha,J.P. Davis,ปถภณ พิริยะ,Rani Purwasih,A. Vindevoghel,J.-L. Canon,Y. Gillerot	1998	33
14	Randomized trial of recombinant human interleukin-3 versus placebo in prevention of bone marrow depression during first-line chemotherapy for ovarian carcinoma. Journal of Clinical Oncology ·L.S. Hofstra,Gunnar B. Kristensen,P.H.B. Willemse,A. Vindevoghel,H. Meden,M. Lahousen,F Oberling,Bengt Sorbe,Michael Crump,I. Sklenar,Wim J. Sluiter,Beate Kiese,Claes G. Tropé,Elisabeth G.E. de Vries	1998	5
15	P102 Adjuvant high-dose medroxyprogesterone acetate (HD-MPA) for early breast cancer. 13 years update of a multicenter randomized trial European Journal of Cancer ·C. Focan,M. Beauduin,E. Salamon,Jacques De Grève,Viviana Otálvaro G.,J.P. Lobelle,F. Majois,Rizkiatul Paidiah,Jan Tytgat,Sebastian Belle,周子花山,A. Vindevoghel	1998	2
16	Docetaxel-lncluced Subungual Hemorrhage Dermatology ·Olivier Vanhooteghem,Josette André,A. Vindevoghel,Chaika Pa,M. Franklin,M. Song	1997	9
17	Levamisole adds granulocyte toxicity to 5FU-based chemotherapies in adjuvant treatment of Dukes B-C colorectal cancer. A preliminary report. PubMed ·P. Janssen,C. Focan,J Bury,M. Beauduin,Dany Brohée,Pedersen, Gunnar Møller, 1943-,Luca Fezzi,S Markiewicz,A. Vindevoghel,J Weerts	1995	1
18	Efficacy of twice daily versus three times daily oral ondansetron in the prevention of chemotherapy induced emesis: A randomized, single-blind, multicentre study Clinical Oncology ·M. Dicato,S. Kaasa,Elisabetta Campora,Harry Bleiberg,Tobias H. Abthoff,A. Vindevoghel,David Cunningham,Agatha Komsic-Vranjkovic,B.K. Upadhyaya	1992	11
19	Experience of the Belgian Society of Medical Oncology with single-administration 5 g/m2 ifosfamide with mesna as second- or third-line therapy in advanced breast cancer Cancer Chemotherapy and Pharmacology ·R. Paridaens,C. Focan,J. Michel,Martine Piccart,E. Salamon,M. Beauduin,Marie-Thérèse Closon,Elias Tueni,A. Vindevoghel,F. Majois,T. Percy C. Kirkpatrick	1990	8
20	Adjuvant Treatment with High Dose Medroxyprogesterone Acetate in Node-Negative Early Breast Cancer A 3-year Interim Report on a Randomized Trial (I) Acta Oncologica ·C. Focan,A Baudoux,M. Beauduin,Teeradon Phlairaharn,Qin Qing-wu,D Ivanowski,J.P. Lobelle,E Longeval,F. Majois,AL. Ramanathan,董龙,E. Salamon,Rizkiatul Paidiah,Jan Tytgat,Sebastian Belle,Bruno Vanderlinden,周子花山,A. Vindevoghel	1989	6

About A. Vindevoghel

A. Vindevoghel is a scholar working on Cancer Research, Oncology, Dermatology, Genetics and Pulmonary and Respiratory Medicine, having authored 23 papers that have together received 868 indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (14 papers), Cancer Treatment and Pharmacology (10 papers), Estrogen and related hormone effects (5 papers), HER2/EGFR in Cancer Research (5 papers), Colorectal Cancer Treatments and Studies (3 papers), Breast Lesions and Carcinomas (3 papers), Advanced Breast Cancer Therapies (2 papers) and Gastric Cancer Management and Outcomes (2 papers). The work is most often cited by research in Cancer Research (474 citations), Oncology (647 citations), Pathology and Forensic Medicine (118 citations), Dermatology (56 citations) and Genetics (96 citations). A. Vindevoghel has collaborated with scholars based in Belgium, Italy and Luxembourg. Frequent co-authors include M. Beauduin, Martine Piccart, Henri Roché, Patrice Viens, Bernard Asselain, Alain Monnier, Jean Genève, M. Spielmann, Daniel Serin and Michel Symann. Their work appears in journals such as Journal of Clinical Oncology, European Journal of Cancer, Annals of Oncology, British Journal of Cancer and European Journal of Cancer Prevention.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact